Press Releases for ALXN

Press Releases
Alexion Reports Third Quarter 2009 Results
Alexion Pharmaceuticals to Report Third Quarter 2009 Results on October 22, 2009
European Commission and U.S. FDA Grant Alexion’s Soliris® (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Reports Second Quarter 2009 Results
BenchmarkJournal.Com Free Analyst Review for QLGC, NEXM, GERN, ENDP, LOGI and ALXN
Alexion Pharmaceuticals to Report Second Quarter 2009 Results on July 23, 2009
Alexion Extends Its Commitment to a Green Footprint Through Its Ambitious New Solar Energy System
Alexion's Soliris® Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
Alexion to Present at the Jefferies & Co. 3rd Annual Healthcare Conference
New Research Presented at EHA Congress Shows That Soliris® Significantly Reduced Hemolysis in Never-Transfused Patients with PNH
Alexion to Present at Investor Conferences
New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes
Researchers to Report on the Investigational Use of Alexion’s Soliris® (Eculizumab) to Prevent Antibody-Mediated Rejection in High-Risk Kidney Transplant Patients
Alexion Reports First Quarter 2009 Results
Alexion Pharmaceuticals to Report First Quarter 2009 Results on April 23, 2009
Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH
Alexion to Present at the 4th Annual Citi Biotech Day
Alexion to Present at the Cowen and Company 29th Annual Health Care Conference
PDL BioPharma Announces Fourth Quarter and Full Year 2008 Financial Results
Alexion Joins NORD and EURORDIS in Supporting the Goals of Rare Disease Day
Alexion’s Soliris(R) (eculizumab) Receives Marketing Approval in Australia for All Patients with PNH
Zacks Analyst Blog Highlights: Durect Corp., Alpharma, Journal Communications, Inc., Alexion Pharmaceuticals Inc. And Procter & Gamble.
Alexion Reports Fourth Quarter and Full Year 2008 Results
New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris® (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion’s Soliris(R) (eculizumab) Receives Marketing Approval in Canada for All Patients with PNH
Alexion Pharmaceuticals To Report Fourth Quarter and Full Year 2008 Results on February 12, 2009
Soliris(R) Receives Orphan Drug Designation in Japan
Alexion to Present at the 27th Annual JP Morgan Healthcare Conference
Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
Alexion to Present at the 20th Annual Piper Jaffray Health Care Conference - Nov 26 2008 12:10AM
Alexion to Present at the 20th Annual Piper Jaffray Health Care Conference - Nov 25 2008 11:50AM
David W. Keiser to Retire as President of Alexion
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
Alexion to Present at Investor Conferences
Alexion Reports Third Quarter 2008 Results
Alexion Pharmaceuticals Invites You to Participate in its Third Quarter 2008 Results Conference Call and Web Cast
Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
Alexion to Present at the UBS Global Life Sciences Conference
Semi-annual Changes to the NASDAQ Q-50 Index - Sep 15 2008 7:12AM
Alexion to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
Alexion Reports Second Quarter 2008 Results
Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
Alexion to Present at the Jefferies & Co. 2nd Annual Healthcare Conference
Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
Alexion to Present at the William Blair 28th Annual Growth Stock Conference
Alexion to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
Alexion to Present at Citi's 2008 Healthcare Conference - May 27 2008 12:52AM
Notice of Time Change for Alexion's Presentation at the Bank of America 2008 Health Care Conference - Jun 1 2008 7:07AM
Alexion to Present at the Bank of America 2008 Health Care Conference - Jun 1 2008 7:06AM
Alexion Reports First Quarter 2008 Results
Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast